Themis Medicare Ltd. (Themis) announced the launch of a novel Opioid Injectable Analgesic REMIFENTANIL under its brand name REMITHEM in the Indian market for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care. Remifentanil was first approved in USA in 1996 and has wide clinical usage & acceptance around the world in major markets including USA, Europe, Japan and other countries and is also well published. Themis Medicare Limited has done pioneering work by conducting phase III trials at 13 centers in India before getting REMIFENTANIL approved by the regulators.

REMITHEM Remifentanil is considered to be a Dial In Opioid Analgesic as it has a quick onset of action, while it also has a very short context sensitive half-life enabling in addition a quick offset of action, while reducing the overall time in the OT and Post operative care room. Clinical studies have documented that REMITHEM is better as compared to Fentanyl injection the currently used Standard of Care from an overall pharmacokinetic, hemodynamic and safety perspective. Various studies also suggest that when used with other anesthetic agents REMITHEM may have synergy and as a result help reduce the dosage of other concomitant anesthetic agents.

REMITHEM being an Opioid Analgeic would be only available for use in hospitals which have the necessary licenses/permissions to use Opioid Analgesics. Based on the product's benefit, REMITHEM appears to offer a unique therapeutic option to Anesthesiologists for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care. In the pre-launch meetings conducted by Themis Medicare Limited leading anesthesiologists at Chennai, Cochin and Delhi expressed the view that with launch of REMITHEM "The Wait is Over".

According to Themis Medicare Limited, REMITHEM will be available as 1 mg and 2 mg vials for Injection. With a strong R&D backup, skilled domestic & export teams, and manufacturing sites, the endeavor at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and REMITHEM launch is yet another step in that direction.